AkzoNobel settles remaining Remeron court case
Pharmaceuticals, coatings and chemicals giant, AkzoNobel, and its US human healthcare business, Organon USA, have settled the remaining claims in an antitrust litigation involving the antidepressant drug Remeron in the US.
Pharmaceuticals, coatings and chemicals giant, Akzo Nobel, and its US human healthcare business, Organon USA, have settled the remaining claims in an antitrust litigation involving the antidepressant drug Remeron in the US.
This settlement will result in Akzo Nobel paying around $US75m (€61.5m) to drug wholesalers who had purchased Remeron directly from Organon.
The move resolves the final claims in a series of lawsuits alleging that the company's conduct involving a patent for the use of Remeron in combination with selective serotonin re-uptake inhibitor-based antidepressants, delayed the market introduction of mirtazapine (a generic version of Remeron) and violated US antitrust laws.
Akzo Nobel said it had opted for commercial reasons to settle rather than defend the action but the settlement is subject to certain conditions, including approval by the Federal District Court of New Jersey.
The company has already reached settlements with generic pharmaceutical manufacturers and several large chain and grocery store pharmacies.